CA2827809A1 - Bispecific binding molecules binding to dll4 and ang2 - Google Patents

Bispecific binding molecules binding to dll4 and ang2 Download PDF

Info

Publication number
CA2827809A1
CA2827809A1 CA2827809A CA2827809A CA2827809A1 CA 2827809 A1 CA2827809 A1 CA 2827809A1 CA 2827809 A CA2827809 A CA 2827809A CA 2827809 A CA2827809 A CA 2827809A CA 2827809 A1 CA2827809 A1 CA 2827809A1
Authority
CA
Canada
Prior art keywords
amino acid
seq
single variable
immunoglobulin single
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2827809A
Other languages
English (en)
French (fr)
Inventor
Andreas Gschwind
Rene Georg OTT
Joachim Boucneau
Marie-Ange Buyse
Erik Depla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44314095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2827809(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CA2827809A1 publication Critical patent/CA2827809A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2827809A 2011-04-01 2012-03-30 Bispecific binding molecules binding to dll4 and ang2 Abandoned CA2827809A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11160920.2 2011-04-01
EP11160920 2011-04-01
PCT/EP2012/055897 WO2012131076A1 (en) 2011-04-01 2012-03-30 BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2

Publications (1)

Publication Number Publication Date
CA2827809A1 true CA2827809A1 (en) 2012-10-04

Family

ID=44314095

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2827809A Abandoned CA2827809A1 (en) 2011-04-01 2012-03-30 Bispecific binding molecules binding to dll4 and ang2

Country Status (23)

Country Link
US (1) US20130078247A1 (enExample)
EP (1) EP2694545B1 (enExample)
JP (1) JP2014511682A (enExample)
KR (1) KR20140016345A (enExample)
CN (2) CN106046167A (enExample)
AP (1) AP2013007086A0 (enExample)
AR (1) AR085919A1 (enExample)
AU (1) AU2012234218A1 (enExample)
BR (1) BR112013025294A2 (enExample)
CA (1) CA2827809A1 (enExample)
CL (1) CL2013002622A1 (enExample)
CO (1) CO6801638A2 (enExample)
EA (1) EA201301109A1 (enExample)
EC (1) ECSP13012996A (enExample)
MA (1) MA35233B1 (enExample)
MX (1) MX337115B (enExample)
PE (1) PE20141157A1 (enExample)
PH (1) PH12013502031A1 (enExample)
SG (1) SG193557A1 (enExample)
TN (1) TN2013000389A1 (enExample)
TW (2) TWI535735B (enExample)
UY (1) UY33997A (enExample)
WO (1) WO2012131076A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CA2865464C (en) * 2012-03-30 2022-07-12 Boehringer Ingelheim International Gmbh Ang2-binding molecules
CA2883880A1 (en) * 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
BR112015006363A2 (pt) * 2012-09-28 2017-08-08 Boehringer Ingelheim Int combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
ES2913205T3 (es) 2014-05-13 2022-06-01 Bioatla Inc Proteínas biológicas activas condicionalmente
CN107540747B (zh) * 2017-08-09 2020-01-24 苏州大学附属儿童医院 抗人dll4单克隆抗体6f12
CN110950967B (zh) * 2019-12-13 2022-05-13 山东民康生物科技有限公司 抗人血清白蛋白纳米抗体与il-2融合蛋白及制备方法
MX2024002962A (es) * 2021-09-10 2024-05-17 Soter Biopharma Pte Ltd Anticuerpo anti-ang2, metodo de preparacion del mismo y aplicacion del mismo.
EP4596579A1 (en) * 2022-09-28 2025-08-06 Kexing Biopharm Co., Ltd. Antibody or antigen-binding fragment capable of identifying ang-2, and bispecific antibody for simultaneously identifying vegf and ang-2
CN116444675B (zh) * 2023-05-11 2023-12-22 亲和(武汉)生命科技有限责任公司 一种Pfu DNA聚合酶纳米抗体及其制备方法和应用
WO2025111816A1 (en) * 2023-11-28 2025-06-05 Eluminex Biosciences Limited Multispecific fusion proteins targeting angiogenic, inflammatory, and/or fibrotic factors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
CN101684158A (zh) 2001-01-17 2010-03-31 特鲁比昂药品公司 结合域-免疫球蛋白融合蛋白
AU2002319402B2 (en) 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
JP4490290B2 (ja) 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション 加水分解安定性マレイミド末端ポリマー
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
AU2006249144B2 (en) * 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
DK1962895T3 (da) * 2005-12-16 2013-03-04 Regeneron Pharma TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
CN101489576A (zh) * 2006-06-06 2009-07-22 健泰科生物技术公司 用于调节血管发育的组合物和方法
WO2007143689A2 (en) 2006-06-06 2007-12-13 Genentech, Inc. Compositions and methods for modulating vascular development
AR061246A1 (es) * 2006-06-06 2008-08-13 Genentech Inc Anticuerpos anti- dill4 y metodos que los usan
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CN101646689A (zh) * 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
CN104497143B (zh) * 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CA2717015A1 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CN102264763B (zh) * 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20110195494A1 (en) * 2009-10-02 2011-08-11 Boehringer Ingelheim International Gmbh Dll4-binging molecules
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2

Also Published As

Publication number Publication date
JP2014511682A (ja) 2014-05-19
EP2694545A1 (en) 2014-02-12
MA35233B1 (fr) 2014-07-03
CO6801638A2 (es) 2013-11-29
AU2012234218A1 (en) 2013-09-05
PE20141157A1 (es) 2014-09-24
KR20140016345A (ko) 2014-02-07
UY33997A (es) 2012-09-28
US20130078247A1 (en) 2013-03-28
CN103596977B (zh) 2016-07-06
CN103596977A (zh) 2014-02-19
CL2013002622A1 (es) 2014-02-14
NZ614243A (en) 2015-04-24
AR085919A1 (es) 2013-11-06
EP2694545B1 (en) 2016-08-24
TN2013000389A1 (en) 2015-01-20
AP2013007086A0 (en) 2013-08-31
TW201302789A (zh) 2013-01-16
MX2013011032A (es) 2013-12-06
TW201302797A (zh) 2013-01-16
PH12013502031A1 (en) 2013-12-16
MX337115B (es) 2016-02-12
ECSP13012996A (es) 2013-12-31
BR112013025294A2 (pt) 2017-06-13
SG193557A1 (en) 2013-11-29
WO2012131076A1 (en) 2012-10-04
EA201301109A1 (ru) 2014-08-29
CN106046167A (zh) 2016-10-26
TWI551612B (zh) 2016-10-01
TWI535735B (zh) 2016-06-01

Similar Documents

Publication Publication Date Title
US20220363744A1 (en) Vegf-binding molecules
CA2827817C (en) Bispecific binding molecules binding to vegf and ang2
US20110195494A1 (en) Dll4-binging molecules
JP5833009B2 (ja) 抗脈管形成療法のための二重特異性結合分子
CA2865464C (en) Ang2-binding molecules
EP2694545B1 (en) Bispecific binding molecules binding to dll4 and ang2
OA16772A (en) Bispecific binding molecules binding to DII4 and Ang2.
NZ614243B2 (en) BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2
HK1171031A (en) Dll4-binding molecules
OA16601A (en) Bispecific molecules binging to VEGF and Ang2.
NZ614249B2 (en) Bispecific binding molecules binding to vegf and ang2

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180403